Released Nov 3, 2026, before the open
10-Q filed Nov 3, 2026, 34 days after period end · 0001193125-26-444376
On November 3, 2026, Faeth Therapeutics, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2026.
The release| Metric | Q3 2026 | Q3 2025 | Q3 2024 | Q3 2023 |
|---|---|---|---|---|
| Net Income | -$20.40M | -$4.57M | -$7.25M | -$7.12M |
| EPS Diluted | -$0.79 | -$3.62 | -$5.77 |
Faeth Therapeutics, Inc. · CIK 1829802 · Engraved from SEC EDGAR
| -$0.28 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Faeth Therapeutics reported a net loss of $20.4 million, or $0.79 per basic and diluted share, for the quarter ended September 30, 2026, compared with a net loss of $4.6 million, or $3.62 per share, for the same quarter of 2025.¶1¶2
Research and development expenses were $11.7 million for the quarter ended September 30, 2026, compared with $2.5 million a year earlier, and general and administrative expenses were $10.4 million, compared with $2.3 million.¶3¶4
Cash, cash equivalents and marketable securities were $174.8 million as of September 30, 2026, compared with $21.2 million as of December 31, 2025.¶5
The FDA granted Fast Track designation to PIKTOR in combination with paclitaxel for advanced or recurrent endometrial cancer with a PI3K/AKT/mTOR pathway alteration.¶6¶7